Eli Lilly Buys Cancer Therapy And Announces Timing Of Weight Loss Pill
Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2.5 billion U.S. in cash. Eli Lilly is purchasing Scorpion’s experimental oral therapy called “STX-478,
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
GlobalData on MSN2d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatmentMediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback